Fulgent Genetics
Update in progressFLGT (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDiagnostics & Research
Fulgent Genetics provides clinical diagnostic and therapeutic development services for physicians, patients, and institutions worldwide. Diagnostics include molecular and genetic testing, plus pathology services in GI, dermatopathology, urology, breast, neuropathology, hematopathology, oncology, and sequencing for hereditary cancer and reproductive health. Therapeutics focus on cancer drug candidates using nanoencapsulation and targeted therapy. The Picture Genetics platform includes probes, algorithms, adaptive learning, and LIMS to identify health markers in DNA. Founded 2011 in El Monte, CA.
Company score
- Sentiment
- -0.34
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.00
- Governance
- -0.54
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.11
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.23
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!